Breast cancer is the most generally diagnosed cancer and the most common cause of cancer death for females all over the world, particularly in the economically developing countries[@b1]. It is well known that breast cancer is a heterogeneous disease, not only in the aspect of various pathogenesis, but also in diversified clinical manifestation and outcome. Meanwhile, breast carcinoma is multifactorial disease, from a certain perspective, along with the combination of polygenic inheritance factor and environmental factor. Accompany with technological advances, more studies related with the genomic variation were conducted, in order to improve diagnosis and treatment for breast cancer patients. Mutations in some high and moderate penetrate genes, such as *BRCA1*, *BRCA2* and *ATM*, were verified to be connected with the increased risk of breast cancer[@b2][@b3]. Nonetheless, these mutations constitute a part of the disease risk and it remains unclarified for the majority of genetic variations related with breast cancer susceptibility, particularly for low penetrate genes. It is noteworthy that genome-wide association studies (GWASs) about hundreds of single nucleotide polymorphisms (SNPs) provide strong evidences in elaborating the associations between low penetrate genes and breast cancer risk.

The *TOX3* gene, formerly known as trinucleotide repeat containing 9 (*TNRC9*), is located in the chromosome 16q 12 and has a tri-nucleotide repeat motive. The gene encoded a protein containing a putative high mobility group (HMG) box[@b4], indicating that it might play a potential role in calcium dependent transcription as a transcription factor[@b5]. In the recent years, the associations between genetic variants in *TOX3* region and breast cancer susceptibility have been validated by GWASs and epidemiological studies in European, Asian and African American populations[@b6][@b7][@b8][@b9][@b10][@b11][@b12][@b13]. The SNP rs3803662 is located in 8 kb upstream of *TOX3*, and the rs12443621 and rs8051542 are both lied in an linkage disequilibrium (LD) block containing the 5′ end of *TOX3*[@b6].

The *TOX3* rs3803662 was identified to exhibit association with breast cancer by GWASs[@b6][@b7][@b10], with ascertainment of the association in Hispanic and non-Hispanic white women by Slattery *et al.*[@b11]. However, no significant association was found between rs3803662 and breast cancer risk in Asian and African ancestry[@b8][@b13]. Analogously, there was no evidence for the association between rs12443621 or rs8051542 and increased risk of breast cancer in Chinese women[@b14][@b15][@b16]. Whereas, Shan *et al.* reported that rs8051542 was significantly correlated with breast cancer risk in Tunisians[@b17]. Additionally, some studies found different relationships of three SNPs and breast cancer risk among different populations, which might result from different sample size or diverse allele frequencies and LD pattern among populations.

Meanwhile, the most recent meta-analysis related to the associations between the above-mentioned 3SNPs with breast cancer risk omitted some important studies[@b18], and thus had limited statistical power to demonstrate the associations. Therefore, we performed an updated meta-analysis to aim to come up with the highest level of evidence for the associations between three SNPs in *TOX3* gene and breast cancer risk among diverse ancestry populations and distinct tumor subtypes stratified by estrogen receptor (ER) or *BRCA1/BRCA2.*

Materials and Methods
=====================

Literature search strategy
--------------------------

We carried out a comprehensive literature search from PubMed and EMBASE databases up to March 2015, using the following search terms "*TOX3*" or "*TNRC9*" and "polymorphism" or "genetic variant" or "rs3803662" or "rs12443621" or "rs8051542" and "breast cancer" or "breast carcinoma" or "breast tumor" . First, we retrieved all potentially relevant articles, whose abstracts contained information related to our research purpose. Second, the references from eligible studies were carefully checked for additional relevant literature. Finally, only the comprehensive or the most recent study was brought into this meta-analysis, in the case that the same study population was included in several different articles.

Selection criteria
------------------

Eligible studies had to fulfill the following criteria: (1) case-control studies or cohort studies evaluating the association between *TOX3* polymorphism (rs3803662, rs12443621 or rs8051542) and breast cancer risk; (2) odds ratio (OR) and 95% confidence interval (CI) or genotype data of rs3803662, rs12443621 or rs8051542 in breast cancer patients and cancer-free female to calculate OR and 95% CI; (3) studies were confined to human female groups; (4) articles in English.

Data extraction
---------------

A standard protocol was applied to extract data. For every eligible study, the following data were extracted: First author's surname, year of publication, country of origin, population ethnicity, genotyping method, the genotype counts in cases and control (TT, CT and CC genotypes for *TOX3* rs3803662; GG, AG and AA genotypes for rs12443621; TT, CT and CC genotypes for rs8051542) and P-value for the HWE in control groups. Two investigators independently extracted the above relative data with any disagreement resolved by discussion. If no consensus wasn't reached, another investigator joined in the discussion. And the final decision was made by the majority of the votes.

Statistical methods
-------------------

The strength of associations between *TOX3* polymorphisms and breast carcinoma risk were estimated by OR with corresponding 95% CI. For all studies, we assessed the association under five different genetic models for calculating OR. Those were homozygote codominant model, heterozygote codominant model, dominant model, recessive model and allele model. Hardy-Weinberg equilibrium (HWE) was assessed by using χ^2^ test to compare expected and actual genotype frequencies among controls of each study. Q-statistic was applied to investigate heterogeneity among studies. P-value greater than 0.1 for Q test suggested a lack of statistically significant heterogeneity, and the fixed-effect model (Mantel-Haenszel method)[@b19] was used to calculate pooled ORs. Otherwise, heterogeneity was present and the random-effect model (DerSimonian-Laird method)[@b20] was more appropriate. In addition, the *I*^*2*^-test was employed to accurately measure the degree of heterogeneity. Furthermore, the *I*^*2*^-value less than 25% was equivalent to mild heterogeneity, and values between 25% and 50% was equivalent to moderate heterogeneity, whereas values greater than 50% was equivalent to large heterogeneity among studies. Potential publication bias was estimated by symmetry of funnel plot of OR versus the standard error of log (OR) and the visual symmetrical plot indicated that there was no publication bias among studies. Sensitivity analyses were conducted to assess the robustness of the results by eliminating each study in turn to show whether the individual data set influenced the pooled OR. Stratified analyses were conducted in terms of ethnicity, estrogen receptor (ER) status, *BRCA1* and *BRCA2* mutation. All statistical tests in this meta-analysis were two-tailed and P-value ≤ 0.05 was considered statistically significant unless otherwise noted. All statistical analyses were performed with Review Manager 5.2 software recommended by Cochrane Collaboration and Comprehensive Meta Analysis V2 software.

Result
======

Study Characteristics
---------------------

Based on the above selection criteria, a total of 37 eligible studies were included in the pooled analyses, involving 97275 cases and 128686 controls for rs3803662 polymorphism[@b7][@b8][@b9][@b10][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46]. For rs12443621, 14 studies[@b8][@b12][@b14][@b15][@b16][@b17][@b24][@b28][@b29][@b31][@b41][@b42][@b45][@b46] involved a total of 17750 cases and 19488 controls. Moreover, there were 13 studies[@b8][@b12][@b15][@b16][@b17][@b28][@b29][@b31][@b39][@b41][@b42][@b45][@b46] with 20965 cases and 21580 controls for rs8051542. Of particular note was that it's smaller than 0.05 for the P-value of Hardy-Weinberg equilibrium in the controls of two studies, Campa *et al.* and Garcia-Closas *et al.*[@b37][@b38], but we still included the two studies after sensitivity analyses were done. Additionally, in three included studies, genotype frequencies were shown separately according to different ethnic groups[@b7][@b31][@b39]. Therefore, the corresponding genotype counts in the study were separately considered for analyses. For rs3803662, five studies[@b11][@b15][@b16][@b26][@b38] concerned with ER subtype of breast cancers and three studies[@b26][@b30][@b35] related with BRCA1/2 mutation carriers were analysed as subgroups. The [Fig. 1](#f1){ref-type="fig"} expounded the study selection process. The [Table 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"} described the main features of these studies, especially for the genotype counts.

Meta-analysis results
---------------------

The mixtures of adjusted and crude estimates were used to calculate pooled ORs. The available adjusted variables of included studies were listed in [supplementary table 1](#S1){ref-type="supplementary-material"}. Owing to large heterogeneity among studies, we used random-effect model to calculate pooled ORs for the associations of rs3803662 and rs12443621 with breast cancer risk. In contrast, fix-effect model was applied to calculate pooled ORs for rs8051542. In aggregate, T-rs3803662 and T-rs8051542 were all statistically associated with increased risk of breast cancer in all genetic models. However, the association between G-rs12443621 and breast cancer risk was only observed in Caucasians under all genetic models. The pooled ORs and 95%CI for these associations in all genetic models were shown in detail in [Table 3](#t3){ref-type="table"}, [4](#t4){ref-type="table"}, [5](#t5){ref-type="table"}, respectively. Forest plots related to the association of rs3803662, rs12443621 and rs8051542 with breast cancer susceptibility in homozygote model were shown in [Fig. 2](#f2){ref-type="fig"}, [Fig. 3](#f3){ref-type="fig"} and [Fig. 4](#f4){ref-type="fig"}, respectively.

In the subgroup analysis by ethnicity, our results indicated statistically significant associations between the three SNPs and breast cancer susceptibility in Caucasians under all genetic models. Nevertheless, as for Asian populations, T-rs3803662 and T-rs8051542 were shown to be statistically significant correlated with increased risk of breast cancer in all genetic models. In addition, there was no evidence for the statistical significant associations between the three SNPs and increased risk of breast cancer in African population which were almost African-American in our study. The pool ORs and 95%CI for these stratified analyses were detailedly shown in [Table 3](#t3){ref-type="table"}, [4](#t4){ref-type="table"}, [5](#t5){ref-type="table"} for all genetic modes.

When stratified by ER status for rs3803662, statistically significant increased risk was found in ER^+^ and ER^−^ tumor ([Fig. 5](#f5){ref-type="fig"} and [Fig. 6](#f6){ref-type="fig"}). Moreover, a stronger association was identified in ER^+^ than ER^−^ subtype for breast cancer risk ([Fig. 7](#f7){ref-type="fig"}). Additionally, our analysis demonstrated that there were significant relationships between elevated risk of breast cancer and *BRCA1/2* mutation carriers for rs3803662 ([Fig. 8](#f8){ref-type="fig"} and [Fig. 9](#f9){ref-type="fig"}). And the details about ORs and 95% CI under all genetic models were shown in [Table 3](#t3){ref-type="table"}.

Sensitivity analyses and publication bias
-----------------------------------------

Sensitivity analyses were conducted to assess the robustness of the results by eliminating each study in turn and all the results were not essentially altered, suggesting that the results of our meta-analysis were statistically stable. Publication bias of the eligible literature was evaluated by funnel plots and the shapes of funnel plots for literature about association between three SNPs and breast cancer risk were mostly symmetrical, indicating that no publication bias was detected.

Discussion
==========

The *TOX3* gene encoded a protein with an HMG box that is considered to be implicated in modification of DNA and chromatin structure[@b47]. Moreover, increased expression of *TOX3* was relevant to bone metastasis in breast cancer patients[@b48]. Whereas, precise biological function of *TOX3* is undetermined. Some GWASs and epidemiological studies have identified the associations of *TOX3* polymorphisms with breast cancer susceptibility. However, study results were not consistent. Hence, in order to resolve the conflict, we performed this meta-analysis of the associations between the *TOX3* rs3803662, rs12443621 and rs8051542 polymorphism and breast cancer risk.

The three SNPs locate in the 5' end of *TOX3* gene and a hypothetical gene LOC643714 on 16q12, and the region is contained in a 133kb linkage disequilibrium (LD) block[@b12]. Based on the International HapMap database, different LD patterns were observed between Asian and European ancestry. SNP rs3803662 was in moderate LD with rs12443621, with a Pearson's correlation coefficient (r^2^) of 0.29 in the HapMap CEU population for European ancestry, but very weak LD was found between these two SNPs (r^2^ = 0.06) in Chinese[@b8]. Similarly, there was very weak association (r^2^ = 0.08) between rs3803662 and rs8051542 located 52 kb apart from each other in Chinese women[@b45]. However, the two SNPs showed moderate association (r^2^ = 0.15) with each other in European populations[@b8]. The substantial differences in genetic architecture among races, such as allele frequencies and LD structures, may partly account for our results which confirmed different association of the three SNPs with breast cancer risk in Caucasians, Asians and African-Americans. Rs3803662-T allele, rs12443621-G allele and rs8051542-T allele were statistically significantly associated with increased risk of breast cancer in Caucasians. Meanwhile, T-rs3803662 and T-rs8051542 were identified as risk factors of breast cancer in Asian populations. However, there was no evidence to prove that the three SNPs in African-Americans and G-rs12443621 in Asians were implicated in the breast tumor susceptibility, which was in line with the previous studies[@b41][@b45]. It's worth mentioning that our study showed that T-rs3803662 and G-rs12443621 were protective factors in African-Americans in spite of no statistical significance.

In general, our study proved that the T-rs3803662 and T-rs8051542 in *TOX3* were correlated with elevated breast cancer risk in all genetic models. It is notable that a previous meta-analysis directed by Chen *et al.*[@b18] has showed that rs3803662 polymorphism was significantly associated with breast cancer risk, but no significant associations were observed for the rs12443621 and rs8051542. In addition, it only included eight case-control studies without stratified analyses. Compared with the previous meta-analysis, our study had more powerful and detailed analyses to prove our results. First and most obviously, more eligible literature and larger sample size were included. Second, the associations between breast cancer risk and rs3803662 polymorphism were considered with respect to ER status and BRCA1/2 mutation carriers. Third, stratified analyses were performed based on Caucasians, Asians and Africans, which was in favor of a more comprehensive understanding the associations in diverse populations. Finally and most importantly, we used mixture of adjusted and crude ORs rather than unadjusted estimates to calculate the pooled ORs. Meanwhile, the original genotype counts of eligible studies were also used to calculate the crude ORs. [Supplementary table 2](#S1){ref-type="supplementary-material"} showed the pooled ORs of the associations between the 3SNPs and breast cancer risk by using crude estimates. And there was no significant difference among the two results of pooled ORs based on different estimates, except for rs12443621. The crude ORs were incorporated to result in marginally association of rs12443621 with breast cancer risk under homozygote, dominant and allele genetic mode, but no association was found by using mixture ORs. That was probably because that adjusted estimates could yield more accurate results. Nevertheless, the two ways both demonstrated the relationship between rs12443621 and elevated risk of breast cancer in Caucasians.

To date, more attention has been paid to the heterogeneity of associations between common genetic variants and breast cancer subtypes. The two large-scale studies[@b37][@b38] and our result identified that rs3803662 polymorphism was associated with both ER^+^ and ER^−^ subtype of breast cancer, in spite of the slightly weaker association for ER^−^ breast cancer. Additionally, our study demonstrated that T-rs3803662 was statistically significant associated with increased risk in ER^+^ breast cancer compared with ER^−^ subtype, which was accordance with the researches done by Stacey *et al.* and Broeks *et al.*[@b7][@b49]. Intriguingly, T-rs8051542 allele and rs12443621 AG/GG genotypes, rather than rs3803662, were significantly associated with elevated risk of ER^+^ breast cancer in Chinese women[@b8][@b16]. By contrast, the significant associations of rs8051542 and rs12443621 were observed with luminal A (ER/PR^+^, Her2^−^) and Her2^+^/ER^−^ breast cancer only among whites, respectively[@b50]. Furthermore, the association was strongly confirmed between rs3803662 and triple-negative tumors[@b25][@b49]. Taken together, these studies indicated that there were somehow connections between the three SNPs in *TOX3* gene and pathological subtype of breast tumor among different populations. And in another aspect, these studies provided further support for the hypothesis that different subtypes stem from diverse etiological pathways. Additionally, rs3803662 SNP in *BRCA1* and *BRCA2* mutation carriers was significantly associated with the increased risk of breast cancer in our analysis, which was in consistent with previous studies[@b26][@b35]. While Latif *et al.* confirmed that the genetic variant was only associated with breast tumor in *BRCA2* mutation carriers[@b30]. Therefore, it's necessary to further elucidate the relevance of rs3803662 to breast cancer risk with *BRAC1* and *BRCA2* mutation.

Despite the advantage of large sample size and stratified analyses, the meta-analysis had several limitations that should be taken into account. First, there was extreme heterogeneity for the outcomes of the association between rs3803662 polymorphism and breast cancer risk. Although we reduced the degree of heterogeneity by stratified analyses based on ethnicity, other sources of heterogeneity were not verified, such as different genotyping methods or tumor types. Second, the sample size of African populations (5462 cases and 7155 controls) was relatively small. Therefore there was insufficient statistical power to demonstrate the associations between the 3SNPs and breast cancer risk in Africans. Third, the criterion of control groups was not uniformly defined. The design of eligible studies was based on population or/and hospital patients, thus there were potential risks of breast cancer in control groups. Fourth, the mixtures of crude and adjusted publish estimates, rather than incorporation of adjusted ORs, were used in the meta-analysis. Because of the lack of some individual data, we were unable to adjust effect size with possible confounders related with lifestyle risk factors, such as age, obesity, smoking, alcohol consumption and menopausal status. Furthermore, we were unable to examine the interaction between genetic variables and environment. In recent years, some studies for gene-environment interactions showed that relative risks of breast cancer correlated with low-penetrance susceptibility variants (including rs3803662) didn't vary significantly with established environmental risk factors, such as reproductive history, menopausal status and body mass index[@b51][@b52][@b53]. Nevertheless, more and more researches have elaborated combined effect of low-penetrance susceptibility loci with breast cancer risk. And the obviously elevated risk stemming from combining many low-penetrant risk alleles supports the polygenic inheritance model of breast cancer[@b44]. Finally, owing to merely include English articles, there might be language bias on some level. Additionally, positive reports are tended to be published, which might make certain bias.

In conclusion, this meta-analysis indicated that there were different associations between the 3SNPs in *TOX3* gene and breast cancer risk in different ethnic groups or subtype tumor. The 3SNPs were associated with the increased risk of breast cancer in Caucasians, while weren't correlated in Africans. Additionally, rs3803662 and rs8051542 were risk factors for breast cancer in Asians. Furthermore, there were stronger associations between rs3803662 polymorphism and breast cancer risk in ER^+^ subtype than ER^−^ tumors. Increased risk of breast cancer associated with rs3803662 was confirmed in *BRCA1/BRCA2* mutation carriers. However, studies with larger sample size, which use uniform genotyping methods and criterion of control groups, have sufficiently corresponding individual data and consider the interactions of gene-gene and gene-environment will be needed to verify our results for *TOX3* rs3803662, rs12443621 and rs8051542 as predisposition markers to breast cancer in clinical application.
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![Forest plot of *TOX3* rs3803662 polymorphism and breast cancer risk.\
Random-effect model was used for the analysis (homozygote codominant model TT vs. CC). The squares and horizontal lines correspond to the specific OR and 95% CI for every study. The area of the squares reflects the study specific weight. The diamond stands for the pooled OR and 95% CI.](srep12773-f2){#f2}

![Forest plot of *TOX3* rs12443621 polymorphism and breast cancer risk.\
Random-effect model was used for the analysis (homozygote codominant model GG vs. AA).](srep12773-f3){#f3}

![Forest plot of *TOX3* rs8051542 polymorphism and breast cancer risk.\
Fixed-effect model was used for the analysis (homozygote codominant model TT vs. CC).](srep12773-f4){#f4}

![Forest plot of *TOX3* rs3803662 polymorphism and breast cancer risk stratified by ER (+).\
Fixed-effect model was used for the analysis (allele model T vs. C).](srep12773-f5){#f5}

![Forest plot of *TOX3* rs3803662 polymorphism and breast cancer risk stratified by ER (−).\
Fixed-effect model was used for the analysis (allele model T vs. C).](srep12773-f6){#f6}

![Forest plot of *TOX3* rs3803662 polymorphism and breast cancer risk in ER+ subtype compared with ER− tumors.\
Fixed-effect model was used for the analysis (allele model T vs. C).](srep12773-f7){#f7}

![Forest plot of *TOX3* rs3803662 polymorphism and breast cancer risk stratified by BRCA1 mutation.\
Fixed-effect model was used for the analysis (allele contrast model T vs. C).](srep12773-f8){#f8}

![Forest plot of *TOX3* rs3803662 polymorphism and breast cancer risk stratified by BRCA2 mutation.\
Fix -effect model was used for the analysis (allele contrast model T vs. C).](srep12773-f9){#f9}

###### Characteristics of studies for the association of *TOX3* rs3803662 with breast cancer risk included in the meta-analysis.

  Author                   Year    Country    Ethnicity           Genotyping method           Case   Control                               
  ----------------------- ------ ----------- ----------- ----------------------------------- ------ --------- ------ ------ ------ ------- ----------
  Stacey[@b7]              2007    Iceland    Caucasian               Illumina                469     1985     2100   1272   6913   9392   0.999
  Stacey[@b7]              2007    Iceland       AA                   Illumina                 95      211     116    130    222     95    0.990
  Stacey[@b7]              2007    Iceland      Asian                 Illumina                155      275     122    147    278     132   0.980
  Stacey[@b7]              2007    Iceland      Mixed                 Illumina                104      275     183    114    340     259   0.891
  He[@b8]                  2014     China       Asian            Sequenom MassARRAY           271      280      72    270    278     72    0.973
  Elematore[@b9]           2014     Chile       Mixed                  TaqMan                  62      185     100    100    371     330   0.786
  Low[@b10]                2013     Japan       Asian       Illumina OmniExpress BeadChip     1801    2705     1016   1496   2739   1254   0.996
  Slattery[@b11]           2011      USA      Caucasian                TaqMan                 204      755     778    202    862     978   0.550
  Udler[@b12]              2010      UK       Caucasian                  NA                   194      942     1041   157    829    1273   0.167
  Ruiz -Narváez[@b13]      2010      USA         AA           Sequenom MassArray iPLEX        188      376     189    214    412     199   0.980
  Jiang[@b14]              2011     China       Asian                 SNaPshot                233      212      48    232    224     54    0.995
  Li[@b15]                 2009     China       Asian                  PCR-LDR                118      141      32    123    128     40    0.470
  Liang[@b16]              2010     China       Asian     SNP stream highthroughput 12-plex   486      413     126    455    464     127   0.603
  Shan[@b17]               2012     Qatar     Caucasian                TaqMan                 147      293     200     78    165     126   0.083
  Long[@b21]               2013      USA         AA                TaqMan/Sequenom            328      613     287    563    1027    469   0.988
  Kim[@b22]                2012     Korea       Asian             Affymetrix/TaqMan           499     1939     1887   577    1967   1677   0.996
  Huo[@b23]                2012      USA       African           Illumina GoldenGate          393      754     362    368    691     324   0.991
  Chan[@b24]               2012   Singapore     Asian                  TaqMan                 541      499     134    629    656     181   0.622
  Stevens[@b25]            2011      USA      Caucasian            iPLEX/Illumina             268     1252     1460   363    1960   2650   0.982
  Mulligan[@b26]           2011    Canada       Mixed                  TaqMan                 585     2652     3109   426    2197   2899   0.730
  Han[@b27]                2011     Korea       Asian                  RT-PCR                 1481    1435     369    1361   1617    516   0.317
  Long[@b28]               2010      USA        Asian       Affymetrix/Sequenom MassARRAY     2934    2761     650    1603   1727    465   0.996
  Long[@b29]               2010      USA      Caucasian                TaqMan                 258     1172     1330   190    1028   1391   0.997
  Latif[@b30]              2010      UK       Caucasian                TaqMan                  84      395     422     19    137     217   0.660
  Barnholtz-Sloan[@b31]    2010      USA         AA              Illumina GoldenGate          196      378     166    182    333     142   0.654
  Barnholtz-Sloan[@b31]    2010      USA      Caucasian          Illumina GoldenGate          133      512     585     89    440     589   0.591
  Gorodnova[@b32]          2010    Russia     Caucasian                RT-PCR                  16      50       74     15     82     77    0.294
  Hemminki[@b33]           2010    Germany    Caucasian      MALDITOF mass spectrometry       154      626     635    124    704    1002   0.982
  Mcinerney[@b34]          2009    Ireland    Caucasian         KASPar SNP genotyping          82      382     486     58    396     532   0.161
  Antoniou[@b35]           2008      UK       Caucasian        TaqMan/MALOI-TOF/iPLEX         497     2173     2422   382    1831   2244   0.756
  Tapper[@b36]             2008      UK       Caucasian             iPLEX Service              76      371     452    196    1137   1647   0.990
  Campa[@b37]              2011    Germany      Mixed                  TaqMan                 1071    3528     3706   1150   4724   5721   0.001
  Garcia-Closas[@b38]      2008      USA        Mixed              TaqMan/MALDITOF            1848    7132     7759   2026   9705   13295  \<0.0001
  Barzan[@b39]             2013    Germany      Asian            Sequenom MassARRAY           482      413      89    961    990     255   0.999
  Barzan[@b39]             2013    Germany    Caucasian          Sequenom MassARRAY            36      140     135     65    369     526   0.979
  Rinella[@b40]            2013      USA      Caucasian           Affymetrix/KASPar           131      335     214    106    366     315   0.985
  Zheng[@b41]              2009      USA         AA              Sequenom MassARRAY           222      404     184    482    891     411   0.984
  Butt[@b42]               2012    Sweden     Caucasian          Sequenom MassARRAY            64      278     353     95    512     780   0.380
  Mizoo[@b43]              2013     Japan       Asian                  TaqMan                 160      230      74    142    227     91    0.987
  Harlid[@b44]             2012    Sweden     Caucasian      MALDITOF mass spectrometry       330     1420     1794   352    1898   2768   0.280
  Zheng[@b45]              2010      USA        Asian                Affymetrix               1401    1325     313    1286   1410    386   0.987
  Tamimi[@b46]             2010      USA      Caucasian         Sequenom iPLEX/TaqMan          54      300     333     50    273     415   0.576

AA: African Americans; NA: not available; HWE: Hardy-Weinberg equilibrium; PCR-LDR : Polymerase chain reaction--ligation detection reaction.

###### Genotypes and P~WHE~ for *TOX3* rs12443621 and rs8051542 polymorphisms included in the study.

  Author                        rs12443621 Genotypes   P~HWE~   rs8051542 Genotypes   P~HWE~                                                               
  ---------------------------- ---------------------- -------- --------------------- -------- ------ ----- ------- ----- ------ ------ ----- ------ ------ -------
  He[@b8] 2014                          110             304             209            115     304    201  0.809    25    199    399    18    175    427   0.989
  Udler[@b12] 2010                      527             1111            546            497     1099   681  0.176    455   1089   611    425   1067   736   0.274
  Jiang[@b14] 2011                      170             239             84             162     251    97   0.990    ---   ---    ---    ---   ---    ---   ---
  Li[@b15] 2009                         106             138             54              97     141    55   0.766    15     82    198     9     90    209   0.854
  Liang[@b16] 2010                      347             507             186            338     519    204  0.850    48    314    670    47    309    708   0.078
  Shan[@b17] 2012                       190             301             147             98     180    85   0.894    138   289    208    46    176    146   0.529
  Chan^24^2012                          404             573             198            532     669    262  0.419    ---   ---    ---    ---   ---    ---   ---
  Long[@b28] 2010                       546             1448            960            554     1469   974  0.998    246   1971   3941   118   1080   2460  0.968
  Long[@b29] 2010                       286             573             286            274     571    297  0.989    336   788    463    279   709    451   0.991
  Barnholtz-Sloan[@b31] 2010            164             370             208            165     329    164  0.999    87    342    313    59    304    295   0.121
  Barnholtz-Sloan[@b31] 2010            337             580             313            242     574    302  0.319    257   587    386    201   559    358   0.501
  Barzan[@b39] 2013                     ---             ---             ---            ---     ---    ---  ---      43    327    614    72    651    1483  0.957
  Barzan[@b39] 2013                     ---             ---             ---            ---     ---    ---  ---      81    155     75    186   473    301   0.994
  Zheng[@b41] 2009                      189             405             216            423     891    470  0.986    80    349    381    170   762    852   0.984
  Butt[@b42] 2012                       165             338             195            275     657    451  0.203    149   338    192    272   637    443   0.119
  Zheng[@b45] 2010                      1001            1486            552            1008    1509   565  0.995    118   961    1960   96    898    2088  0.963
  Tamimi[@b46] 2010                     151             337             193            130     366    241  0.659    132   359    194    135   380    220   0.193

P~HWE~: P value of Hardy-Weinberg equilibrium for control groups.

###### Stratified analysis of *TOX3* rs3803662 polymorphism on breast cancer.

  Variables            N   TT versus CC            CT versus CC  TT + CT versus CC       TT versus CT + CC  T versus C                                                                               
  ------------------- ---- ---------------------- -------------- ---------------------- ------------------- ---------------------- --------- ---------------------- --------- ---------------------- ---------
  Total                43  1.311 (1.221--1.407)      \<0.001     1.151 (1.103--1.201)         \<0.001       1.160 (1.088--1.237)    \<0.001  1.200 (1.140--1.263)    \<0.001  1.145 (1.106--1.186)    \<0.001
  Ethnicity                                                                                                                                                                                          
  Asian                13  1.245 (1.076--1.440)      \<0.001     1.121 (1.013--1.241)         \<0.001       1.162 (1.030--1.311)    \<0.001  1.133 (1.049--1.223)    \<0.001  1.112 (1.034--1.195)    \<0.001
  Caucasian            19  1.483 (1.371--1.604)       0.029      1.212 (1.153--1.275)          0.005        1.259 (1.194--1.327)    \<0.001  1.347 (1.280--1.418)     0.332   1.220 (1.171--1.271)    \<0.001
  African              6   0.929 (0.837--1.032)       0.240      0.961 (0.841--1.099)          0.044        0.989 (0.877--1.116)     0.048   0.952 (0.878--1.032)     0.52    0.962 (0.914--1.012)     0.296
  Mixed                5   1.440 (1.288--1.611)       0.017      1.200 (1.109--1.298)          0.004        1.084 (0.927--1.268)    \<0.001  1.358 (1.294--1.425)     0.265   1.202 (1.126--1.282)    \<0.001
  ER (+)               4   1.493 (1.391--1.603)       0.696      1.241 (1.188--1.297)          0.468        1.312 (1.262--1.364)     0.284   1.410 (1.321--1.505)     0.594   1.225 (1.189--1.262)     0.524
  ER (−)               4   1.104 (0.885--1.376)       0.073      1.134 (1.066--1.206)          0.491        1.135 (1.008--1.278)     0.079   1.282 (1.163--1.414)     0.327   1.118 (1.064--1.175)     0.519
  ER (+) vs. ER (−)    5   1.382 (0.998--1.915)       0.016      1.073 (1.002--1.149)          0.582        1.086 (1.019--1.157)     0.668   1.093 (0.986--1.212)     0.883   1.067 (1.016--1.121)     0.468
  BRCA1                3   1.249 (1.087--1.436)       0.811      1.107 (1.022--1.198)          0.933        1.130 (1.048--1.219)     0.888   1.194 (1.044--1.365)     0.833   1.113 (1.050--1.181)     0.822
  BRCA2                3   1.102 (0.921--1.319)       0.911      1.276 (1.018--1.599)          0.030        1.310 (1.039--1.650)     0.017   1.207 (1.018--1.432)     0.458   1.230 (1.037--1.459)     0.023

N: Numbers of data sets; P~H~: P-value of Q-test for heterogeneity test; P~H~ \< 0.1 indicates that there is heterogeneity and random-effect model is used to calculate pooled OR~s~ and 95% CI. Otherwise, fixed-effect model is used.

###### Stratified analysis of *TOX3* rs12443621 polymorphism on breast cancer.

  Variables     N   GG versus AA           AG versus AA   GG + AG versus AA      GG versus AG + AA   G versus A                                                                           
  ------------ ---- ---------------------- -------------- ---------------------- ------------------- ---------------------- ------- ---------------------- ------- ---------------------- -------
  Total         15  1.072 (0.975--1.180)   0.005          1.033 (0.958--1.113)   0.020               1.049 (0.983--1.121)   0.047   1.061 (0.996--1.131)   0.069   1.033 (0.985--1.083)   0.003
  Ethnicity                                                                                                                                                                               
   Asian        7   1.006 (0.927--1.092)   0.885          1.002 (0.936--1.073)   0.663               1.006 (0.941--1.075)   0.696   1.007 (0.945--1.072)   0.802   1.000 (0.956--1.046)   0.843
   Caucasian    6   1.264 (1.143--1.398)   0.201          1.156 (1.062--1.258)   0.281               1.163 (1.078--1.256)   0.147   1.181 (1.089--1.280)   0.273   1.125 (1.070--1.183)   0.190
   African      2   0.854 (0.720--1.012)   0.117          0.863 (0.658--1.132)   0.062               0.931 (0.803--1.079)   0.355   0.926 (0.794--1.080)   0.371   0.928 (0.853--1.009)   0.145

N: Numbers of data sets; P~H~: P-value of Q-test for heterogeneity test; P~H~ \<0.1 indicates that there is heterogeneity and random-effect model is used to calculate pooled OR~s~ and 95% CI. Otherwise, fixed-effect model is used.

###### Stratified analysis of *TOX3* rs8051542 polymorphism on breast cancer.

  Variables     N   TT versus CC           CT versus CC   TT + CT versus CC      TT versus CT + CC   T versus C                                                                           
  ------------ ---- ---------------------- -------------- ---------------------- ------------------- ---------------------- ------- ---------------------- ------- ---------------------- -------
  Total         15  1.304 (1.210--1.405)   0.378          1.125 (1.076--1.175)   0.647               1.159 (1.112--1.208)   0.689   1.198 (1.121--1.280)   0.420   1.135 (1.099--1.171)   0.388
  Ethnicity                                                                                                                                                                               
   Asian        6   1.370 (1.185--1.584)   0.886          1.141 (1.075--1.211)   0.812               1.164 (1.101--1.231)   0.917   1.200 (1.041--1.383)   0.708   1.148 (1.093--1.206)   0.786
   Caucasian    7   1.29 (1.181--1.425)    0.107          1.128 (1.046--1.215)   0.281               1.199 (1.116--1.288)   0.557   1.226 (1.082--1.389)   0.079   1.138 (1.086--1.191)   0.137
   African      2   1.186 (0.941--1.494)   0.189          1.030 (0.896--1.183)   0.917               1.030 (0.913--1.161)   0.996   1.145 (0.970--1.351)   0.407   1.066 (0.964--1.179)   0.318

N: Numbers of data sets; P~H~: P-value of Q-test for heterogeneity test; P~H~ \<0.1 indicates that there is heterogeneity and random-effect model is used to calculate pooled OR~s~ and 95% CI. Otherwise, fixed-effect model is used.
